圣湘生物: 圣湘生物科技股份有限公司关于2025年半年度募集资金存放与实际使用情况的专项报告

Core Viewpoint - The report details the fundraising status and usage of funds by Shengxiang Biotechnology Co., Ltd. as of June 30, 2025, ensuring compliance with regulatory requirements and transparency in fund management [1][2]. Fundraising Basic Situation - The total amount raised through the initial public offering (IPO) was RMB 2,019,200,000, with a net amount of RMB 1,869,269,811.32 after deducting issuance costs of RMB 149,930,188.68 [1][2]. - The IPO involved the issuance of 40,000,000 shares at a price of RMB 50.48 per share [1]. Current Fund Usage and Balance - As of June 30, 2025, the cumulative amount used from the raised funds was RMB 1,822,056,102.71, leaving a balance of RMB 54,644,163.20 [2]. - Major expenditures included: - Precision Intelligent Molecular Diagnosis System Production Base Project: RMB 304,182,475.85 - Marketing Network and Information Technology Upgrade Project: RMB 104,945,715.54 - R&D Center Upgrade Project: RMB 100,238,100.00 - Permanent Supplement to Working Capital: RMB 1,312,689,811.32 [2]. Fund Management Situation - The company has established a fundraising management system to ensure the effective use of funds and protect investor rights, adhering to relevant laws and regulations [2]. - Funds are stored in dedicated accounts, and strict approval procedures are followed for fund usage [2]. Fund Usage in Special Accounts - As of June 30, 2025, the company maintained six special fundraising accounts, with a total balance of RMB 54,644,163.20 [3][4][5]. Actual Fund Usage for the Year - No prior investments or replacements of fundraising projects occurred during the reporting period [6]. - The company has not used idle funds to temporarily supplement working capital [6]. - A resolution was passed to manage temporarily idle funds of up to RMB 140 million for safe and liquid investment products, valid for 12 months [6][8]. Changes in Fund Usage - There were no changes in the fundraising projects or any transfers or replacements of projects as of June 30, 2025 [7]. Issues in Fund Usage and Disclosure - The company has complied with all legal and regulatory requirements regarding the use and disclosure of fundraising, with no violations reported [7].